
    
      The study includes a 3-month, randomized, double-blind treatment period in which participants
      receive either galcanezumab or placebo, followed by a 9-month open-label extension in which
      all participants receive galcanezumab. Enrollment in the European Union may also include
      participants 6 to 11 years of age.
    
  